Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.79
AMGN's Cash to Debt is ranked higher than
59% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. AMGN: 0.79 )
AMGN' s 10-Year Cash to Debt Range
Min: 0.27   Max: 8.25
Current: 0.79

0.27
8.25
Equity to Asset 0.35
AMGN's Equity to Asset is ranked higher than
57% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. AMGN: 0.35 )
AMGN' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.84
Current: 0.35

0.33
0.84
F-Score: 5
Z-Score: 2.51
M-Score: -2.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 29.98
AMGN's Operating margin (%) is ranked higher than
95% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. AMGN: 29.98 )
AMGN' s 10-Year Operating margin (%) Range
Min: -14.21   Max: 43.12
Current: 29.98

-14.21
43.12
Net-margin (%) 24.74
AMGN's Net-margin (%) is ranked higher than
95% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. AMGN: 24.74 )
AMGN' s 10-Year Net-margin (%) Range
Min: -25.2   Max: 34.22
Current: 24.74

-25.2
34.22
ROE (%) 21.01
AMGN's ROE (%) is ranked higher than
95% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. AMGN: 21.01 )
AMGN' s 10-Year ROE (%) Range
Min: -11.85   Max: 39.26
Current: 21.01

-11.85
39.26
ROA (%) 7.39
AMGN's ROA (%) is ranked higher than
92% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. AMGN: 7.39 )
AMGN' s 10-Year ROA (%) Range
Min: -9.01   Max: 28.29
Current: 7.39

-9.01
28.29
ROC (Joel Greenblatt) (%) 74.09
AMGN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. AMGN: 74.09 )
AMGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -29.14   Max: 94.09
Current: 74.09

-29.14
94.09
Revenue Growth (%) 16.10
AMGN's Revenue Growth (%) is ranked higher than
88% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. AMGN: 16.10 )
AMGN' s 10-Year Revenue Growth (%) Range
Min: 5.9   Max: 29.3
Current: 16.1

5.9
29.3
EBITDA Growth (%) 9.20
AMGN's EBITDA Growth (%) is ranked higher than
86% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. AMGN: 9.20 )
AMGN' s 10-Year EBITDA Growth (%) Range
Min: 1.1   Max: 25.3
Current: 9.2

1.1
25.3
EPS Growth (%) 11.50
AMGN's EPS Growth (%) is ranked higher than
87% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. AMGN: 11.50 )
AMGN' s 10-Year EPS Growth (%) Range
Min: 2.3   Max: 28.2
Current: 11.5

2.3
28.2
» AMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AMGN Guru Trades in Q3 2013

Stanley Druckenmiller 231,000 sh (New)
Steven Cohen 63,283 sh (+187.92%)
Jeremy Grantham 2,668,851 sh (+29.16%)
Mario Gabelli 22,420 sh (+26.95%)
John Hussman 250,000 sh (+25%)
Vanguard Health Care Fund 10,758,455 sh (unchged)
Paul Tudor Jones Sold Out
Ray Dalio Sold Out
Pioneer Investments 696,092 sh (-2.31%)
Bill Frels 11,180 sh (-2.82%)
PRIMECAP Management 35,812,225 sh (-4.11%)
Mark Hillman 8,069 sh (-10.03%)
Ken Fisher 5,632 sh (-12.18%)
Dodge & Cox 160,052 sh (-38.73%)
Alan Fournier 90,000 sh (-41.94%)
Jim Simons 71,000 sh (-94.43%)
Manning & Napier Advisors, Inc 5,241 sh (-95.93%)
» More
Q4 2013

AMGN Guru Trades in Q4 2013

Ray Dalio 7,513 sh (New)
Joel Greenblatt 23,170 sh (New)
Paul Tudor Jones 7,697 sh (New)
Jim Simons 862,245 sh (+1114.43%)
Steven Cohen 751,083 sh (+1086.86%)
Jeremy Grantham 3,122,746 sh (+17.01%)
Mario Gabelli 23,620 sh (+5.35%)
Ken Fisher 5,837 sh (+3.64%)
Stanley Druckenmiller 231,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Pioneer Investments 694,971 sh (-0.16%)
PRIMECAP Management 35,508,354 sh (-0.85%)
Mark Hillman 7,912 sh (-1.95%)
Bill Frels 10,780 sh (-3.58%)
Dodge & Cox 136,620 sh (-14.64%)
Vanguard Health Care Fund 8,775,155 sh (-18.43%)
Alan Fournier 70,000 sh (-22.22%)
John Hussman 175,000 sh (-30%)
» More
Q1 2014

AMGN Guru Trades in Q1 2014

RS Investment Management 3,840 sh (New)
Louis Moore Bacon 3,450 sh (New)
Ken Fisher 49,887 sh (+754.67%)
Alan Fournier 150,000 sh (+114.29%)
Mario Gabelli 32,565 sh (+37.87%)
Pioneer Investments 783,138 sh (+12.69%)
Jeremy Grantham 3,290,249 sh (+5.36%)
Bill Frels 10,780 sh (unchged)
Ray Dalio Sold Out
Stanley Druckenmiller Sold Out
Joel Greenblatt Sold Out
Vanguard Health Care Fund 8,213,855 sh (-6.4%)
PRIMECAP Management 32,161,744 sh (-9.42%)
John Hussman 150,000 sh (-14.29%)
Dodge & Cox 105,757 sh (-22.59%)
Paul Tudor Jones 3,985 sh (-48.23%)
Jim Simons 333,349 sh (-61.34%)
Steven Cohen 13,665 sh (-98.18%)
» More
Q2 2014

AMGN Guru Trades in Q2 2014

Joel Greenblatt 9,938 sh (New)
Daniel Loeb 450,000 sh (New)
John Buckingham 56,216 sh (New)
Paul Tudor Jones 9,013 sh (+126.17%)
Mario Gabelli 60,335 sh (+85.28%)
Ken Fisher 85,316 sh (+71.02%)
Alan Fournier 236,000 sh (+57.33%)
Bill Frels 10,991 sh (+1.96%)
RS Investment Management 3,840 sh (unchged)
Louis Moore Bacon 3,450 sh (unchged)
Steven Cohen 238,008 sh (unchged)
Jeremy Grantham 3,260,920 sh (-0.89%)
PRIMECAP Management 31,853,844 sh (-0.96%)
Vanguard Health Care Fund 8,049,455 sh (-2%)
Jim Simons 310,645 sh (-6.81%)
Dodge & Cox 85,857 sh (-18.82%)
John Hussman 50,000 sh (-66.67%)
Pioneer Investments 142,948 sh (-81.75%)
» More
» Details

Insider Trades

Latest Guru Trades with AMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Reduce -66.67%0.93%$110.29 - $126.07 $ 158.8837%50000
Daniel Loeb 2014-06-30 New Buy0.65%$110.29 - $126.07 $ 158.8837%450000
Joel Greenblatt 2014-06-30 New Buy0.02%$110.29 - $126.07 $ 158.8837%9938
Mario Gabelli 2014-06-30 Add 85.28%0.02%$110.29 - $126.07 $ 158.8837%60335
Ken Fisher 2014-06-30 Add 71.02%0.01%$110.29 - $126.07 $ 158.8837%85316
PRIMECAP Management 2014-03-31 Reduce -9.42%0.46%$113.48 - $127.47 $ 158.8831%32161744
Vanguard Health Care Fund 2014-03-31 Reduce -6.4%0.2%$113.48 - $127.47 $ 158.8831%8213855
John Hussman 2014-03-31 Reduce -14.29%0.2%$113.48 - $127.47 $ 158.8831%150000
Joel Greenblatt 2014-03-31 Sold Out 0.06%$113.48 - $127.47 $ 158.8831%0
Ray Dalio 2014-03-31 Sold Out 0.01%$113.48 - $127.47 $ 158.8831%0
Mario Gabelli 2014-03-31 Add 37.87%0.01%$113.48 - $127.47 $ 158.8831%32565
Ken Fisher 2014-03-31 Add 754.67%0.01%$113.48 - $127.47 $ 158.8831%49887
Dodge & Cox 2014-03-31 Reduce -22.59%$113.48 - $127.47 $ 158.8831%105757
Vanguard Health Care Fund 2013-12-31 Reduce -18.43%0.76%$106.28 - $118.688 $ 158.8840%8775155
John Hussman 2013-12-31 Reduce -30%0.45%$106.28 - $118.688 $ 158.8840%175000
Joel Greenblatt 2013-12-31 New Buy0.06%$106.28 - $118.688 $ 158.8840%23170
Ray Dalio 2013-12-31 New Buy0.01%$106.28 - $118.688 $ 158.8840%7513
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Amgen Inc

Daniel Loeb Comments on Amgen Inc - Oct 22, 2014

Since its founding in 1980, Amgen (AMGN) (“the company”) has been a pioneer in the biotechnology industry, successfully discovering, developing, and marketing therapeutic agents that have meaningfully impacted human health. From 1989 to 2002, Amgen grew five revolutionary biologic drugs into billion dollar blockbuster products in oncology, nephrology, and inflammation. Today, Amgen is a $105 billion market cap company with annual revenues of nearly $20 billion and annual net income e of over $5billion.

Considering this track record, Amgen’s long‐term underperformance relative to its biotech peers is surprising. The company has a compelling mix of long‐duration, high‐margin mature products like Neulasta and Enbrel, and a number of exciting high growth assets, including recently launched blockbusters like Prolia and Xgeva along with innovative late-stage pipeline assets like evolocumab. Yet, using nearly any valuation metric, the Company trades at a substantial discount to peers. Amgen even trades at a discount to the US pharmaceutical sector, despite superior revenue and earnings growth rates. Amgen’s current discount to fair valuation – and the lack of structural hurdles to closing this gap – make it an attractive investment opportunity. Third Point is now one of the company’s largest shareholders.

Amgen has all the hallmarks of a hidden value situation, one of our favorite investment themes. The company does not receive proper credit from investors for either the cash generative potential of its mature products or the coming financial impact of its growth assets. In the mature products segment, we believe revenues will be sustainable and concerns about potential erosion are overstated. With respect to Amgen’s pipeline, we believe the market underappreciates how disruptive some of its new products will be. Our conviction about the company’s growth pipeline has been bolstered by our discussions with Third Point’s newly created Scientific and Medical Advisory Board (“SMAB”) led by renowned oncologist Dr. David Agus. Dr. Agus has helped us assemble a world‐class team of scientists and physicians to assist in our evaluation of therapeutic companies and their clinicalassets.1

We believe the obscured fundamental value and investor skepticism that have led to Amgen’s valuation discount can be easily unlocked. Throughout our due diligence and discussions with sell‐side analysts and other investors, it became clear that the market has penalized Amgen for several key reasons: 1) its historical lack of R&D productivity; 2) more than a decade of flat operating margins; and 3) the suspension of its share repurchase program in 2013 following its $9 billion acquisition of Onyx Pharmaceuticals.

First, on R&D productivity, our analyses confirm that Amgen’s R&D efforts have been more costly and less efficient than those of its biotech peers. Despite investing a cumulative $32 billion in R&D since 2002, over 75% of Amgen’s current revenues still come from products introduced before that year. Amgen also appears to spend significantly more money on its late‐stage pipeline assets than any of its biotech peers – both in absolute terms and relative to the number of development projects. Given this sparse output versus to investment, we believe improvements are needed in Amgen’s R&D evaluation process, a hypothesis supported by members of our SMAB.

Second, the market has rightfully punished Amgen for having flat operating margins since 2002 despite a 3x increase in revenues, a failure we attribute to excessive spending. For starters, the bloated cost structure is troubling given that Amgen competes in specialized therapeutic areas which require small, highly focused sales and marketing efforts, and generates the majority of its revenues from just a few well‐established, popular drugs. Another puzzle is that while the biotechnology industry has seen substantial improvements in manufacturing efficiency, Amgen has not demonstrated any of the obvious economies of scale (e.g., procurement, sourcing) that should have been realized. Against this backdrop, the company’s lack of operating margin leverage over this period is doubly surprising. Given its revenue growth, we are convinced that Amgen should have seen meaningful operating margin expansion since 2002, a shortcoming which we believe management has now acknowledged. We believe recent efforts to trim costs do not even scratch the potential opportunity.

Third, in 2013, Amgen’s management made a questionable capital allocation decision: the company purchased Onyx Pharmaceuticals at a 40%+ premium for $9 billion in cash while halting its own share repurchase program. At the time, the company said that its buyback would remain halted until 2016. Based on corporate filings, during the deal negotiations, Amgen had concerns about Onyx’s lead compound, Kyprolis, and renegotiated to reduce the price. Since the acquisition closed, Amgen has disclosed that while the ASPIRE trial for Kyprolis met its clinical endpoints, its sister FOCUS trial failed to show clinical benefit and introduced potential concerns over renal‐adverse events. Instead of the Onyx purchase, Amgen could have accretively repurchased over 10% of its shares outstanding, at the depressed valuation of just 4x sales. Beyond Onyx, we question whether the return on Amgen’s $17 billion in M&A spending since 2002 (on top of the aforementioned $32 billion in R&D spending) has been economically justified, both in absolute terms and also relative to other transactions in the sector. We are challenged to identify any “home‐run” acquisitions and, while still early, believe that most of these transactions will turn out to show mediocre returns.

We believe that Amgen management can directly address all three sources of legitimate investor frustration and, based on our discussions to date with management, we believe that they will. While we applauded Amgen’s first steps in July to target the company’s inflated cost structure by rationalizing its US facilities footprint and creating centers of R&D excellence in San Francisco and Boston, we believe much more can and should be done. Immediate actions Amgen can take to create shareholder value include: 1) Focusing its R&D efforts; 2) Providing long‐term margin guidance demonstrating a commitment to reducing a bloated cost structure; and 3) Creating clarity on additional shareholder returns.

We have also asked the company to seriously consider a more radical option, one first proposed by Geoffrey Porges at Sanford Bernstein. It is well‐established that disparate business units generally benefit from operating separately due to distinct corporate cultures, superior efficiencies, and a greater focus for employees and management alike. Given the diverse nature of its assets – cash‐generative Mature Products and R&D‐intensive Growth Products – we believe that Amgen could benefit from a separation into distinct operating units with separate financial statements and should seriously consider separating into two companies (e.g., a MatureCo and a GrowthCo). Internally, each business would have different priorities: MatureCo would focus on efficiency and cashflow, while GrowthCo would emphasize product development and innovation. Externally, each business would be valued with different metrics: MatureCo on a dividend yield and GrowthCo on a peer‐based sales or earnings multiple. Our own extensive diligence suggests that a break‐up of Amgen is feasible and that purported constraints such as tax strategy and supply chain management can be managed.

A separation of Amgen into MatureCo and GrowthCo would likely be very well received by investors. We expect that MatureCo would receive a valuation based on its dividend yield while GrowthCo would be valued, like peers, on a high growth multiple on earnings, reflective of the burgeoning pipeline. Importantly, however, we believe that a separation would not just be good for shareholders, but that it is a more effective way of running each business. In particular, we believe that the benefits to GrowthCo would be the most meaningful: talent retention, more rapid decision making, and ultimately, accelerated development of new therapies to improve countless lives. We urge Amgen management and a committee of independent directors to conduct their own in‐depth evaluation of this strategic option and share their findings with investors.

We believe there are three ways to win in Amgen, depending on the path management takes from here. If Amgen is simply valued at one turn below its pharmaceutical peers at 17x earnings – a change we expect to be driven by management’s current restructuring plans – the stock should be worth $189 per share by the end of 2016. If Amgen fully seizes the opportunities outlined in our recommendations to focus its R&D, announce structural expense reductions, and accelerate capital deployment, we believe 2017 EPS will reach $12.82 (versus consensus of $11.12 currently), implying a share price of $218 on the same multiple. We see the most upside, however, in the scenario where Amgen strategically separates into two standalone business, as we have encouraged management to consider. In two years, we expect that such a separation could create almost $249 per share in total value, over 80% upside to the current share price.

CEO Bob Bradway and his team have been open‐minded and receptive to our ideas to date and we firmly believe that the company is at an inflection point. The company’s upcoming Analyst Day presents an excellent chance for Amgen management to take bold action and provide clear direction for the company, its investors, and its employees. We hope to maintain our constructive dialogue with management as the company moves towards closing its valuation gap.

From Daniel Loeb (Trades, Portfolio)’s Third Point Q3 2014 Investor Letter.

Check out Daniel Loeb latest stock trades

Mario Gabelli Comments on Amgen Inc. - Jan 06, 2014

Amgen Inc. (0.2%) (AMGN - $111.94 - NASDAQ)(AMGN) is one of the largest biotechnology companies in the world, with medicines for cancer, kidney dialysis, osteoporosis, and other conditions. Given its large size and mature product portfolio, revenue growth has slowed, but the company has been able to cut costs and repurchase shares to sustain double digit earnings per share growth. Earlier this year, Amgen offered to acquire Onyx Pharmaceuticals Inc. (less than 0.1%) to bolster its oncology portfolio, with Nexavar for liver cancer and Kyprolis for blood cancers. On Aug 25, after a brief auction, Amgen agreed to pay $125 per share, or $10.4 billion, for Onyx. While initially dilutive to earnings, this acquisition provides significant visibility into Amgen's future, with two blockbuster drugs that could eventually generate over $5 billion in annual sales. 

 

From Mario Gabelli (Trades, Portfolio)'s third quarter 2013 commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Amgen Inc

Daniel Loeb Comments on Amgen Inc
Since its founding in 1980, Amgen (AMGN) (“the company”) has been a pioneer in the biotechnology industry, successfully discovering, developing, and marketing therapeutic agents that have meaningfully impacted human health. From 1989 to 2002, Amgen grew five revolutionary biologic drugs into billion dollar blockbuster products in oncology, nephrology, and inflammation. Today, Amgen is a $105 billion market cap company with annual revenues of nearly $20 billion and annual net income e of over $5billion. Read more...
Mario Gabelli Comments on Amgen Inc.
Amgen Inc. (0.2%) (AMGN - $111.94 - NASDAQ)(AMGN) is one of the largest biotechnology companies in the world, with medicines for cancer, kidney dialysis, osteoporosis, and other conditions. Given its large size and mature product portfolio, revenue growth has slowed, but the company has been able to cut costs and repurchase shares to sustain double digit earnings per share growth. Earlier this year, Amgen offered to acquire Onyx Pharmaceuticals Inc. (less than 0.1%) to bolster its oncology portfolio, with Nexavar for liver cancer and Kyprolis for blood cancers. On Aug 25, after a brief auction, Amgen agreed to pay $125 per share, or $10.4 billion, for Onyx. While initially dilutive to earnings, this acquisition provides significant visibility into Amgen's future, with two blockbuster drugs that could eventually generate over $5 billion in annual sales.  Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.40
AMGN's P/E(ttm) is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 24.40 )
AMGN' s 10-Year P/E(ttm) Range
Min: 10.4   Max: 38.45
Current: 24.4

10.4
38.45
P/B 5.00
AMGN's P/B is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. AMGN: 5.00 )
AMGN' s 10-Year P/B Range
Min: 1.8   Max: 5.38
Current: 5

1.8
5.38
P/S 6.26
AMGN's P/S is ranked higher than
86% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.97 vs. AMGN: 6.26 )
AMGN' s 10-Year P/S Range
Min: 3.01   Max: 10.44
Current: 6.26

3.01
10.44
PFCF 19.40
AMGN's PFCF is ranked higher than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 19.40 )
AMGN' s 10-Year PFCF Range
Min: 8.78   Max: 49.8
Current: 19.4

8.78
49.8
EV-to-EBIT 20.84
AMGN's EV-to-EBIT is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 20.84 )
AMGN' s 10-Year EV-to-EBIT Range
Min: 8   Max: 27.5
Current: 20.84

8
27.5
PEG 2.57
AMGN's PEG is ranked higher than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 2.57 )
AMGN' s 10-Year PEG Range
Min: 0.25   Max: 2.54
Current: 2.57

0.25
2.54
Shiller P/E 29.40
AMGN's Shiller P/E is ranked higher than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 29.40 )
AMGN' s 10-Year Shiller P/E Range
Min: 12.82   Max: 80.07
Current: 29.4

12.82
80.07
Current Ratio 4.36
AMGN's Current Ratio is ranked higher than
75% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. AMGN: 4.36 )
AMGN' s 10-Year Current Ratio Range
Min: 1.31   Max: 6.33
Current: 4.36

1.31
6.33
Quick Ratio 3.99
AMGN's Quick Ratio is ranked higher than
75% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. AMGN: 3.99 )
AMGN' s 10-Year Quick Ratio Range
Min: 1.17   Max: 5.75
Current: 3.99

1.17
5.75

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.45
AMGN's Dividend Yield is ranked higher than
73% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. AMGN: 1.45 )
AMGN' s 10-Year Dividend Yield Range
Min: 0.48   Max: 1.89
Current: 1.45

0.48
1.89
Dividend Payout 0.33
AMGN's Dividend Payout is ranked higher than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 0.33 )
AMGN' s 10-Year Dividend Payout Range
Min: 0.22   Max: 0.56
Current: 0.33

0.22
0.56
Yield on cost (5-Year) 1.40
AMGN's Yield on cost (5-Year) is ranked higher than
63% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. AMGN: 1.40 )
AMGN' s 10-Year Yield on cost (5-Year) Range
Min: 0.48   Max: 1.89
Current: 1.4

0.48
1.89
Share Buyback Rate 7.40
AMGN's Share Buyback Rate is ranked higher than
99% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. AMGN: 7.40 )
AMGN' s 10-Year Share Buyback Rate Range
Min: 8.3   Max: -7.5
Current: 7.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.20
AMGN's Price/DCF (Projected) is ranked higher than
99% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 1.20 )
AMGN' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 6.23
Current: 1.2

0.59
6.23
Price/Median PS Value 1.40
AMGN's Price/Median PS Value is ranked higher than
77% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.92 vs. AMGN: 1.40 )
AMGN' s 10-Year Price/Median PS Value Range
Min: 0.72   Max: 5.19
Current: 1.4

0.72
5.19
Price/Peter Lynch Fair Value 2.50
AMGN's Price/Peter Lynch Fair Value is ranked higher than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 2.50 )
AMGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.58   Max: 3.34
Current: 2.5

0.58
3.34
Earnings Yield (Greenblatt) 4.80
AMGN's Earnings Yield (Greenblatt) is ranked higher than
94% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. AMGN: 4.80 )
AMGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.6   Max: 12.5
Current: 4.8

3.6
12.5
Forward Rate of Return (Yacktman) 12.74
AMGN's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. AMGN: 12.74 )
AMGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.5   Max: 70.3
Current: 12.74

1.5
70.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:AMG.Germany, 04332.Hongkong, AMGN34.Brazil, AMG N.Mexico
Amgen Inc., a Delaware corporation was incorporated in 1980. The Company is a biotechnology medicines company. It discovers, develops, manufactures and delivers innovative human therapeutics. Its medicines help patients fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. The Company operates in one business segment which includes human therapeutics. The Company's principal products are: Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body's response to inflammatory diseases. Its marketed products include Sensipar/Mimpara , a small molecule calcimimetic that lowers serum calcium levels; Vectibix , a monoclonal antibody that binds specifically to the epidermal growth factor receptor ; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition to its marketed products, it has various product candidates in mid- to late-stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. The Company's manufacturing operations consist of bulk manufacturing, formulation, fill and finish and distribution activities for all of its principal products as well product candidates. Its manufacturing facilities are located in the United States, Puerto Rico and the Netherlands.
» More Articles for AMGN

Headlines

Articles On GuruFocus.com
Amgen: Stronger Drug Portfolio with Acquisition Oct 28 2014 
Daniel Loeb Comments on Amgen Inc Oct 22 2014 
Third Point Q3 2014 Investor Letter Oct 22 2014 
Amgen: Stronger Drug Portfolio with Acquisition Sep 22 2014 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Weekly 52-Week Highs Highlight: ABT, SWK, LMT, AMGN Sep 13 2014 
After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
Amgen Inc: As Good as It Gets? Feb 20 2014 
You Can No Longer Ignore Biotech Feb 07 2014 

More From Our Partners
Amgen's (AMGN) CEO Bob Bradway on Q3 2014 Results - Earnings Call Transcript Oct 27 2014 - SEEKINGALPHA

More From Other Websites
Today's Market Thorns, Roses, and All Time Highs... Oct 29 2014
Amgen’s operating margins have been flat despite revenue growth Oct 29 2014
AMGEN INC Files SEC form 10-Q, Quarterly Report Oct 29 2014
FOMC: Not necessarily more “hawkish”, but certainly appeared a bit “less dovish” Oct 29 2014
Stocks Trim Losses After Fed Report; Solarwinds Soars Oct 29 2014
Why Nomura Upgraded Amgen Oct 29 2014
Amgen Up on Strategic Initiatives and 2015 Guidance Oct 29 2014
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen Oct 29 2014
Third Point Partners ups stake in Amgen Oct 29 2014
Amgen, bowing to hedge fund pressure, to cut up to 1,100 more jobs Oct 28 2014
Market Thorns, Roses, and All Time Highs... Oct 28 2014
[video]Stocks Rally Tuesday; Dow Posts Triple-Digit Gain, Topping 17,000 Oct 28 2014
Twitter and Amgen are big market movers Oct 28 2014
US STOCKS-Wall St jumps 1 pct, S&P ends above key level Oct 28 2014
US STOCKS-Wall St jumps 1 pct, S&P ends above key level Oct 28 2014
Amgen has attractive, high-growth assets Oct 28 2014
Amgen Refuses To Split, But Plans Hearten Investors Oct 28 2014
Amgen climbs after strong sales figures Oct 28 2014
How Many? Amgen Rejects a Break Up, But Will Slash Another 1,100 Jobs Oct 28 2014
Amgen 2015 outlook tops estimates, no plan to split; shares jump Oct 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK